SequelSEC

Viatris Inc VTRS

Pharmaceutical Preparations · CIK 0001792044 · Fiscal year ends 1231

Revenue
$14.74B
Fiscal year ended 2026-06-30
Operating income
-$87.30M
Fiscal year ended 2026-06-30
Free cash flow
$1.95B
Fiscal year ended 2026-06-30

Viatris Inc (VTRS) reported revenue of $14.74B for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Viatris Inc’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Viatris Inc income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$14.74B
Cost of revenue$9.60B
Gross profit$5.13B
Operating income-$87.30M
Net incomeUnavailable
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax income-$662.20M
Income tax expense-$251.50M
Diluted EPSUnavailable
Selling, general & administrative$3.98B
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

Viatris Inc balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$886.50M
Total assets$35.04B
Current assets$10.06B
Total liabilities$20.78B
Current liabilities$6.35B
Total equity incl. NCI$14.26B
Temporary (mezzanine) equityUnavailable
Inventory$3.93B
Accounts receivable$3.13B
Goodwill$6.65B
Long-term debt$11.61B
Accounts payableUnavailable

Cash flow

Viatris Inc cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$2.33B
Capital expenditures$376.00M
Investing cash flow-$84.30M
Financing cash flow-$1.91B
Net change in cash$322.20M
Stock-based compensation$172.30M
Common dividends paidUnavailable
Common share repurchases$303.00M
Depreciation & amortization$2.80B

Derived

Viatris Inc derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$1.95B
Gross margin34.8%
Operating margin-0.6%
FCF margin13.3%
SBC / revenue1.2%
Current ratio1.58x
Revenue YoY growth4.5%
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenue2.6%
Long-term debt / equity0.81x
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open VTRS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.